crizotinib and Abscess

crizotinib has been researched along with Abscess* in 2 studies

Other Studies

2 other study(ies) available for crizotinib and Abscess

Article	Year
Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC. Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:12 We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. It expands the known spectrum of complications of Crizotinib.. Clinical case report.. Multiple aseptic and recurrent abscesses were observed in the liver, thoracic wall as well as in both kidneys in a 75-year-old female patient suffering from NSCLC who had been treated with Crizotinib for almost 2 years. After discontinuation of the treatment the abscesses dissolved spontaneously and did not reoccur.. Aseptic abscesses under treatment with Crizotinib are not restricted to the kidneys as described before, but can also occur in other abdominal organs as the liver and even in the thoracic wall. We postulate that this finding may point to a yet unknown not tissue-dependent mechanism of action. Topics: Abscess; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors	2021
Crizotinib-induced Rectal Perforation with Abscess. Internal medicine (Tokyo, Japan), 2017, Dec-01, Volume: 56, Issue:23 An 86-year-old Japanese man was diagnosed with stage IV lung adenocarcinoma. The patient was treated with crizotinib after echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement was detected from his pleural effusion. He subsequently developed abdominal pain and rebound tenderness in the right lower abdomen. Contrast-enhanced abdominal CT showed a low-density area in the abdominal cavity. The size of the abscess was decreased by drainage and the administration of antibiotics. Fistulography revealed a fistula from the rectum to the abscess, and a diagnosis of lower intestinal tract perforation with abscess formation was made. Crizotinib was discontinued and treatment with alectinib was initiated. The patient remains under treatment as an outpatient at our department without adverse effects. Topics: Abscess; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fistula; Humans; Intestinal Perforation; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rectum; Treatment Outcome	2017

Article

Year

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.

Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:12

We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. It expands the known spectrum of complications of Crizotinib.. Clinical case report.. Multiple aseptic and recurrent abscesses were observed in the liver, thoracic wall as well as in both kidneys in a 75-year-old female patient suffering from NSCLC who had been treated with Crizotinib for almost 2 years. After discontinuation of the treatment the abscesses dissolved spontaneously and did not reoccur.. Aseptic abscesses under treatment with Crizotinib are not restricted to the kidneys as described before, but can also occur in other abdominal organs as the liver and even in the thoracic wall. We postulate that this finding may point to a yet unknown not tissue-dependent mechanism of action.

Topics: Abscess; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors

2021

Crizotinib-induced Rectal Perforation with Abscess.

Internal medicine (Tokyo, Japan), 2017, Dec-01, Volume: 56, Issue:23

An 86-year-old Japanese man was diagnosed with stage IV lung adenocarcinoma. The patient was treated with crizotinib after echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement was detected from his pleural effusion. He subsequently developed abdominal pain and rebound tenderness in the right lower abdomen. Contrast-enhanced abdominal CT showed a low-density area in the abdominal cavity. The size of the abscess was decreased by drainage and the administration of antibiotics. Fistulography revealed a fistula from the rectum to the abscess, and a diagnosis of lower intestinal tract perforation with abscess formation was made. Crizotinib was discontinued and treatment with alectinib was initiated. The patient remains under treatment as an outpatient at our department without adverse effects.

Topics: Abscess; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fistula; Humans; Intestinal Perforation; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rectum; Treatment Outcome

2017